shutterstock_1644459649_ascannio
Ascannio / Shutterstock.com
20 February 2020AmericasRory O'Neill

Health campaigners call for greater checks on AbbVie/Allergan merger

Trade unions and consumer groups have urged the Federal Trade Commission (FTC) to intervene in the planned $63 billion merger of drugmakers AbbVie and Allergan, arguing it would “substantially harm competition”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
28 January 2020   Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab and Zenpep, in a development meant to satisfy antitrust regulations in the US.
Americas
20 July 2020   AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica, a new report has revealed.
Americas
27 May 2021   AbbVie and its exclusive licensee have settled a patent lawsuit against Taro Pharmaceutical over a generic rosacea drug.

More on this story

Big Pharma
28 January 2020   Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab and Zenpep, in a development meant to satisfy antitrust regulations in the US.
Americas
20 July 2020   AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica, a new report has revealed.
Americas
27 May 2021   AbbVie and its exclusive licensee have settled a patent lawsuit against Taro Pharmaceutical over a generic rosacea drug.

More on this story

Big Pharma
28 January 2020   Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab and Zenpep, in a development meant to satisfy antitrust regulations in the US.
Americas
20 July 2020   AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica, a new report has revealed.
Americas
27 May 2021   AbbVie and its exclusive licensee have settled a patent lawsuit against Taro Pharmaceutical over a generic rosacea drug.